Oxymetholone: I. Evaluation in a Comprehensive Battery of Genetic Toxicology and In Vitro Transformation Assays

Toxicologic Pathology

Volumn 27, Issue 5, 1999, Pages 501-506

  Holden, Henry E ^a   Studwell, Debbie ^a   Majeska, Jenness B ^a  

^a NONE

Author keywords

Ames test; carcinogenicity; cytogenetics; genetic toxicology; micronucleus test; mutagenicity; Oxymetholone; SHE assay

Indexed keywords

OXYMETHOLONE;

ARTICLE; CARCINOGEN TESTING; CONTROLLED STUDY; CYTOGENETICS; ESCHERICHIA COLI; GENE MUTATION; GENETIC TOXICOLOGY; GENOTOXICITY; LYMPHOCYTE; MUTAGEN TESTING; NONHUMAN; PRIORITY JOURNAL; SALMONELLA; SYRIAN HAMSTER; TRANSGENIC MOUSE;

ANABOLIC AGENTS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; COLONY COUNT, MICROBIAL; CRICETINAE; CYTOGENETIC ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FEMALE; HUMANS; LYMPHOCYTES; MALE; MESOCRICETUS; MICE; MICRONUCLEUS TESTS; MITOTIC INDEX; MUTAGENICITY TESTS; MUTATION; OXYMETHOLONE; RATS; SALMONELLA TYPHIMURIUM; TUMOR CELLS, CULTURED;

ANIMALIA; BACTERIA (MICROORGANISMS); CRICETINAE; ESCHERICHIA COLI; MAMMALIA; MESOCRICETUS AURATUS; MUS MUSCULUS; SALMONELLA;

EID: 0032849278     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700501     Document Type: Article

References (22)

1. Anonymous (1995). ANADROL®-50. In: Physician's Desk Reference, 49th ed. Medical Economics Data Production Co., Montvale, New Jersey, pp. 2458-2459.
2. Bootman J. (1996). Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organized by the U.S. National Toxicology Program. Environ. Mol. Mutagen. 27: 237-243.
3. Buckley W., Yesalis C., Friedl K., Anderson W., Streit A., and Wright J. (1988). Estimated prevalence of anabolic steroid use among male high school seniors. J. Am. Med. Assoc. 260: 3441-3445.
4. Clive D., Caspary W., Kirby PE, Krehl R., Moore M., Mayo J., and Oberly TJ (1987). Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutat. Res. 189: 143-156.
5. Donehower L. (1996). The p53-deficient mouse: A model for basic and applied cancer studies. Semin. Cancer Biol. 7: 269-278.
6. Evans HJ and O'Riordan ML (1975). Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat. Res. 31: 135-148.
7. Hennge UR, Baumann M., Maleba R., Brockmeyer N., and Goos M. (1996). Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br. J. Nutr. 75: 129-138.
8. Holden H., Majeska J., and Studwell D. (1997). A direct comparison of mouse and rat bone marrow and blood as target tissues in the micronucleus assay. Mutat. Res. 391: 87-89.
9. Holden HE, Stoll RE, and Blanchard KT (1999). Oxymetholone: II. Evaluation in the Tg.AC transgenic mouse model for detection of carcinogens. Toxicol. Pathol. 27: 507-512 (this issue).
10. Holden HE, Stoll RE, Spalding JW, and Tennant RW (1997). Evaluation of oxymetholone in the Tg.AC transgenic mouse model for accelerated carcinogenicity detection. Fundam. Appl. Toxicol. 36: 178-179.
11. Holden HE, Stoll RE, Spalding JW, and Tennant RW (1998). Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: Evaluation of husbandry and housing factors. J. Appl. Toxicol. 18: 19-24.
12. Kastenbaum M., and Bowman K. (1970). Tables for determining the statistical significance of mutation frequencies. Mutat. Res. 9: 527-549.
13. Kerckaert G., Brauninger R., LeBoeuf R., and Isfort R. (1996). Use of the Syrian hamster embryo cell transformation assay for carcinogenicity prediction of chemicals currently being tested by the National Toxicology Program in rodent bioassays. Environ. Health Perspect. 104: 1075-1084.
14. Kerckaert G., Isfort R., Carr G., Aardema M., and LeBoeuf R. (1996). A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. Mutat. Res. 356: 65-84.
15. LeBeouf R., Kerckaert G., Aardema M., Gibson D., Brauninger R., and Isfort R. (1996). The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutat. Res. 356: 85-127.
16. Leder A., Kuo A., Cardiff R., Sinn E., and Leder P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: Effect of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA 87: 9178-9182.
17. MacGregor JT, Wehr CM, Henika PR, and Shelby MD (1990). The erythrocyte micronucleus test: Measurement at steady state increases assay efficiency and permits integration with toxicity studies. Fundam. Appl. Toxicol 14: 513-522.
18. Maron DM and Ames BN (1983). Revised methods for the Salmonella mutagenicity test. Mutat. Res. 113: 173-215.
19. National Toxicology Program (1998). Management Status Report, April. Department of Health and Human Services, National Institutes of Health, National Institute for Envionmental Health Sciences, Research Triangle Park, North Carolina, p. 13.
20. Stoll RE, Holden HE, Barthel CH, and Blanchard KT (1999). Oxymetholone: III. Evaluation in the p53+l- transgenic mouse model. Toxicol. Pathol. 27: 513-518 (this issue).
21. Studwell D., Holden HE, and Majeska JB (1997). Oxymetholone: A non-genotoxic carcinogen? Environ. Mol. Mutagen. 29(S28): 49.
22. Zeiger E., Anderson B., Haworth S., Lawlor T., and Mortelmans K. (1991). Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ. Mol. Mutagen. 19: 2-141.